Selected article for: "acute respiratory syndrome and lung thrombosis"

Author: Abdulgayoom, Mohammed; Abdelmahmuod, Elabbass; Elfaki, Ahmed; Halabiya, Malik A
Title: Cerebral Venous Sinus Thrombosis as an Unexpected Complication of COVID-19 Pneumonia
  • Cord-id: w1vlw4vr
  • Document date: 2021_7_19
  • ID: w1vlw4vr
    Snippet: Coronavirus disease 2019 (COVID-19) is commonly associated with acute respiratory distress syndrome and acute cardiac and renal injuries. However, thromboembolic events are also prevalent in COVID-19. The pathogenesis of COVID-19 hypercoagulability is not well known but may be linked to the cytokine storm induced by a viral infection or endothelial damage that triggers a cascade leading to hypercoagulability. Because vascular endothelium has angiotensin-converting enzyme 2-like lung tissue, COVI
    Document: Coronavirus disease 2019 (COVID-19) is commonly associated with acute respiratory distress syndrome and acute cardiac and renal injuries. However, thromboembolic events are also prevalent in COVID-19. The pathogenesis of COVID-19 hypercoagulability is not well known but may be linked to the cytokine storm induced by a viral infection or endothelial damage that triggers a cascade leading to hypercoagulability. Because vascular endothelium has angiotensin-converting enzyme 2-like lung tissue, COVID-19 targets lung tissue and vascular endothelium, leading to thrombosis. We present a rare case of a young patient with COVID-19 who presented with thrombosis of the cerebral venous system managed with anticoagulation. This case highlights the need for heightened awareness of this atypical but potentially treatable complication of the COVID-19 disease spectrum.

    Search related documents:
    Co phrase search for related documents
    • activity relationship and lopinavir ritonavir: 1, 2, 3
    • activity relationship and low molecular weight: 1, 2
    • activity relationship and lupus erythematosus: 1
    • acute cardiac and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute cardiac and liver function: 1, 2, 3, 4, 5, 6
    • acute cardiac and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7
    • acute cardiac and lopinavir ritonavir hydroxychloroquine: 1, 2, 3
    • acute cardiac and low molecular weight: 1, 2
    • acute cardiac and low molecular weight heparin: 1, 2
    • acute cardiac and lupus erythematosus: 1
    • admission day and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • admission day and lopinavir ritonavir hydroxychloroquine: 1, 2, 3, 4, 5
    • admission day and low molecular weight: 1, 2, 3, 4, 5, 6, 7
    • admission day and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • admission day and lupus erythematosus: 1
    • liver function and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • liver function and lopinavir ritonavir hydroxychloroquine: 1, 2, 3, 4, 5
    • liver function and low molecular weight: 1